



**KOMMODO**  
THERAPEUTICS

---

## Company Overview

July 2025

# Kommodo's Cell-Based Protein Production Platform

Uniquely Focused On:




Delivering a **Cost-Effective** Therapeutic Platform


Leveraging Existing and **Proven T-Cell Science**

Administration in **Out-Patient Settings**

# Protein-Deficiencies Unleash Relentless Damage



*Developmental Defects*



*Organ Failure*



*Intellectual disabilities*

*Premature Death*

Industry is attempting to respond with:

Gene Therapy

Protein Replacement

Cell-Based Therapies



# Rare Diseases Are Prevalent –and Often Protein-Based

~20-25k patients suffer from: \***lack of protein production** \***dysfunctional protein structure/function** \***improper protein trafficking/processing**

GENE THERAPY PROTEIN REPLACEMENT MARKET

Regenerative Medicine, Organ Transplant, Factor Deficiencies like Hemophilia B

LYSOSOMAL STORAGE DISORDERS  
(\$6.2B w/ ~9.7% CAGR)

Fabry, Gaucher, *Batten Deficiency* & Pompe Diseases

MPS-II, III, IV and VI - *Maroteaux–Lamy syndrome, Morquio A syndrome*

MPS NEXT

MPS  
NOW

MPS-I

# Kommodo has developed a cell-based therapeutic\* that moves ahead of the pack

---

Out-Patient Treatment With Simple Blood Draw Collection

Uptake of Engineered Cells in the Tissue

Permanent & Continuous Secretion of Missing Protein




# Kommodo's Protein-T Platform

Utilizes Inherent T Cell Properties for Protein Delivery

## Addressing neurocognitive disease

T cells take permanent residence in all tissues of the body, including the brain and CNS



T Cells

Target Cell

Non-viral

## PROTEIN - T

Therapeutic Protein


## In Vivo Expansion

T cells are long-lasting (decades) and can be expanded *in vivo* via vaccination

## Tissue-specific Delivery


T cells can be programmed to home and reside in specific tissues

# Why T Cells for Protein Delivery?




## Long-term Persistence

Engineered, autologous T cells have demonstrated decades-long persistence




## Established Safety

Thousands of patients safely infused with engineered T cells



## Tissue Distribution

T cells take residence in all human tissues, including the brain and CNS



## Standardized Manufacturing

T cell isolation and non-viral engineering is well established

# The Fountain of Youth

## Turning Myth Into Mechanism

---

We're transforming the dream of healthy longevity into a therapeutic reality by programming cells to:

*Repair tissue*

*Modulate inflammation*

*Secrete regenerative proteins*

*Recalibrate immune aging*

We're not addressing aging by its symptoms.  
**We're addressing its biological roots.**



# Longevity's Robust Global Market Potential

Total Addressable Market (including Wellness, Pharma, Tech): Over \$600B by 2030!



**Market.** Global longevity and anti-senescence therapy market exhibiting robust growth and expanding therapeutic applications.

- Current market size reached \$28.9B in 2024
- Projected growth to \$46.6B by 2033 globally
- Strong CAGR of 21-23% for Cell therapies



## HEVOLUTION

**Leading Hubs & Ecosystems.** USA (Boston, San Fran), Switzerland, Israel, Singapore, KSA, UAE (Abu Dhabi).

- HNWIs driving early adoption (Bezos, Thiel, Young, Angermayer, Milner)
- Select R&D Hub clinics expanding treatment options rapidly
- Healthcare systems integrating precision anti-aging interventions options
- Early Investors: Hevolution Foundation, Cambrian Bio, Juvenescence Ltd, Bezos Expeditions, Apollo Ventures, Life



**Segment.** Cell therapy market specifically growing from \$4.8B to \$37-84B by 2032-33.

- Senolytics market projection: \$4.18B-\$8.72B
- North America leads with 40%+ market share

**\$28.9B**  
CURRENT MARKET  
SIZE

**\$46.6B**  
BY 2033

**21-23%**  
CAGR GROWTH

# Kommodo's Approach

## Proprietary T Cell Engineering Platform


---

Kommodo addresses:

- Immunosenescence
- Chronic Inflammation
- Regenerative Failure

Includes but isn't limited to secretion of:

- Sirtuin-activating peptides
- Klotho
- Anti-inflammatory cytokines (e.g., IL10)
- Tissue-regenerative factor proteins (e.g., GDF11)



**Scientific Technical Appendix Slides with Proof Points  
available under NDA**

# Proven Record of Success

## Kommodo's Leadership Team & Legacy



- Joined Faculty in 2015
- Translational Lab
- >\$45M in Funding
- 2<sup>nd</sup> US CRISPR Trial



**Branden Moriarity, PhD**  
Co-Founder & CTO

- Associate Professor
- Genetic engineer
- 13+ years in C&GT
- Translational experience
- Serial entrepreneur



**Beau Webber, PhD**  
Co-Founder & CSO

- Associate Professor
- Immunologist
- 13+ years in C&GT
- Translational experience
- Serial entrepreneur



**Jeff Liter**  
Seasoned Biotech CEO

- 5 Biotech CEO Roles
- 14+ years in C&GT
- Conducted 6 Clinical Trials
- 3 Successful Exits
- Serial entrepreneur



- \$1.7M Raised | >\$3.5M NIH
- Non-viral transposon system for stable gene transfer
- Sold in 2019 for >4.8x return



- \$12M Raised | >\$8M NIH
- CAR-T (cancer; autoimmune)
- Translated *TC Buster* CAR-T (Stage: Clinical)
- Concept to clinic in 18 mths
- Treated 5 pts to date

# Well-Established IP Estate


NAME	TYPE	OWNER(S)	STATUS	OTHER
“Genetically Engineered T Cell for Cell Therapy”	Patent Application	University of Minnesota	Pending (Filed 3/16/22)	Commitment to nationalize the patent in Japan and EU
“Genetically Modified Gamma Delta T Cells and Methods of Making and Using”	Patent Application	University of Minnesota	Pending (Filed 8/9/21)	Commitment to nationalize the patent in Japan and EU
“T Cell Engineering Using CRISPER/Cas9 for Precise Gene Transfer and the Use of the Engineered T Cells to Treat Protein or Enzyme Deficiencies”	Patent Application	University of Minnesota	Pending (Filed ??/??/22)	
Protein T	Exclusive License	University of Minnesota	Pending (Finalizing terms)	Grants Kommodo sole right to commercialize technology
<i>TC Buster</i> Transposon (US11278570B2) for Human Cell Engineering	Non-Exclusive License	Bio-Techne	Pending	Moriarity, Webber and Liter developed this system at B-MoGen Biotechnologies (acquired 2019)

# Seeking \$5M Series Seed



# Timeline to Value

Inflection Achievements





# KOMMODO

THERAPEUTICS

**Thank You**

**Jeff Liter**

Email: [Liter@kommodotx.com](mailto:Liter@kommodotx.com)

Phone: (612) 309-7653